---
title: "Vraylar (cariprazine), all indications: Drug interactions questions"
description: "Drug interactions questions on Vraylar (cariprazine) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What are the drug interactions with Vraylar? Which CYP3A4 inhibitors interact with Vraylar? Does grapefruit juice interact with Vraylar? Does cannabis interact with Vraylar? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine), all indications: Drug interactions questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)

## Drug interactions

<a id="vraylar-drug-interactions"></a>

### What are the drug interactions with Vraylar?

> “Strong or Moderate CYP3A4 Inhibitors 
> Clinical Impact: 
> Concomitant use of VRAYLAR with a strong or moderate CYP3A4 inhibitor 
> increases the exposures of cariprazine and its major active metabolite, 
> didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone [see 
> Clinical Pharmacology (12.3)].  
>
> Intervention: 
> If VRAYLAR is used with a strong or moderate CYP3A4 inhibitor, reduce 
> VRAYLAR dosage [see Dosage and Administration (2.6)].  
>
> CYP3A4 Inducers 
> Clinical Impact: 
> CYP3A4 is responsible for the formation and elimination of the active 
> metabolites of cariprazine. The effect of CYP3A4 inducers on the exposure of 
> VRAYLAR has not been evaluated, and the net effect is unclear [see Clinical 
> Pharmacology (12.3)].  
>
> Intervention: 
> Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended 
> [see Dosage and Administration (2.1, 2.6)].”

Source: [VRAYLAR: Prescribing information, page 26, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=26)

<a id="vraylar-cyp3a4-inhibitor-examples"></a>

### Which CYP3A4 inhibitors interact with Vraylar?

> “Strong CYP3A4 inhibitors: ceritinib, clarithromycin, cobicistat, elvitegravir and ritonavir, idelalisib, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, nefazodone, nelfinavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telithromycin, tipranavir and ritonavir, voriconazole
>
> Moderate CYP3A4 inhibitors: aprepitant, ciprofloxacin, conivaptan, crizotinib, diltiazem, dronedarone, erythromycin, fluconazole, imatinib, isavuconazole, verapamil, grapefruit juice,<sup>†</sup> cannabis<sup>2</sup>
>
> These examples are considered a guide and not considered a comprehensive list of all possible drugs that may fit these categories.
>
> Not all of these products have been studied with VRAYLAR.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=Strong%20CYP3A4%20inhibitors%3A%20ceritinib%2C%20clarithromycin%2C,have%20been%20studied%20with%20VRAYLAR.)

On the page, select: More examples of CYP3A4 inhibitors3:

<a id="vraylar-grapefruit"></a>

### Does grapefruit juice interact with Vraylar?

> “Moderate CYP3A4 inhibitors: aprepitant, ciprofloxacin, conivaptan, crizotinib, diltiazem, dronedarone, erythromycin, fluconazole, imatinib, isavuconazole, verapamil, grapefruit juice,<sup>†</sup> cannabis<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=Moderate%20CYP3A4%20inhibitors%3A%20aprepitant%2C%20ciprofloxacin%2C,fluconazole%2C%20imatinib%2C%20isavuconazole%2C%20verapamil%2C%20grapefruit)

On the page, select: More examples of CYP3A4 inhibitors3:

> “<sup>†</sup>The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (eg, high dose, double strength) or more commonly as a “moderate CYP3A inhibitor” when another preparation was used (eg, low dose, single strength).”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=effect%20of%20grapefruit%20juice%20varies,%28eg%2C%20low%20dose%2C%20single%20strength%29.)

On the page, select: More examples of CYP3A4 inhibitors3:

<a id="vraylar-cannabis"></a>

### Does cannabis interact with Vraylar?

> “Strong and moderate CYP3A4 inhibitors can include, but are not limited to, prescription and nonprescription products such as ketoconazole, nefazodone, and cannabis<sup>2,3</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=Strong%20and%20moderate%20CYP3A4%20inhibitors%20can,such%20as%20ketoconazole%2C%20nefazodone%2C%20and)

> “There have been no VRAYLAR drug interaction studies with either nefazodone or cannabis”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=There%20have%20been%20no%20VRAYLAR,with%20either%20nefazodone%20or%20cannabis)

<a id="vraylar-proton-pump-inhibitor"></a>

### Can Vraylar be taken with a proton pump inhibitor?

> “VRAYLAR can be coadministered with a PPI. It does not affect VRAYLAR exposure at steady state<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=VRAYLAR%20can%20be%20coadministered%20with,affect%20VRAYLAR%20exposure%20at%20steady)

> “Co-administration of pantoprazole (40 mg/day), a proton pump inhibitor, with VRAYLAR (6 mg/day) in 
> patients with schizophrenia for 15 days did not affect cariprazine exposure at steady-state, based on Cmax 
> and AUC0-24. Similarly, no significant change in exposure to DCAR and DDCAR was observed.”

Source: [VRAYLAR: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=34)

## Related pages
- [Medical information: Vraylar (cariprazine): All indications](https://www.evicenter.com/medical-information/vraylar)
- [Indication](https://www.evicenter.com/medical-information/vraylar/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vraylar/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/vraylar/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vraylar/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vraylar/storage-and-supply)
